Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …

Introduction Previously, we developed a database of 693 patients with NSCLC and
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …

Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …

Sensitizing mutations in epidermal growth factor receptor (EGFR) are associated with
positive responses to anti-EGFR-targeted therapy, leading to a new era of treatment for non …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent first-line
standard of care in unresectable EGFR mutation-positive (EGFRm+) non-small cell lung …

Passaro et al. Afatinib in NSCLC harboring EGFR mutations 384 skin rash and diarrhea, in
this group of patients there were an improvement of global health status and QoL, physical …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

Introduction: Based on the results of several randomised controlled trials, epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based …

Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …

The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) afatinib improves
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …